It's pretty rare to see an “Underperform” rating on a med-tech stock these days, but Becton Dickinson (NYSE:BDX) carries more than Johnson & Johnson (NYSE:JNJ), Abbott (NYSE:ABT), and Cepheid (Nasdaq:CPHD)
combined. I won't pretend to have read all the research reports out
there, but it seems that most of those analysts who are
cautious/negative on BD are so because of the stock's very robust
valuation and concerns about both near-term and long-term growth in the
diagnostics business. I too see these shares as overpriced relative to
the likely growth trajectory, and wouldn't be a buyer at these levels.
Click this link for the full piece:
http://www.investopedia.com/stock-analysis/080113/becton-dickinson-already-priced-excellence-bdx-abt-rhhby-cphd-holx.aspx
No comments:
Post a Comment